Penn Medicine Lancaster General Health’s Ann B. Barshinger Cancer Institute now offers the advanced cancer treatment CAR T-cell immunotherapy, a groundbreaking immunotherapy treatment that was developed at Penn Medicine in Philadelphia.

CAR T (Chimeric Antigen Receptor T-Cell) is a type of cancer therapy that uses specially modified immune cells from a patient’s own body. T-cells, a type of white blood cell, are removed from the patient and reprogrammed to find and attack cancer cells when reinfused into the bloodstream.

Penn Medicine is a global leader in immunotherapy research that expands the safety and effectiveness of CAR T. CAR T was the first gene therapy to be approved by the Food and Drug Administration (FDA) and has brought a new era of cancer treatment options.

CAR T-cell therapy is used to treat patients with certain kinds of aggressive blood cancers that have not responded to one or more therapies, such as large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.

For more information on CAR T-cell therapy, please visit our website lghealth.org.

Share This Page: